BioScrip, Inc. (NASDAQ:BIOS) reported Q2 2017 earnings this Morning, coming in at ($0.26) per share, missing Wall Street’s estimates of ($0.10) per Share. Revenue for the quarter came in at $218.11 million missing the streets estimates of $220.05 million
Analyst Coverage For BioScrip, Inc. (NASDAQ:BIOS)
These are 3 Buy Ratings .
The current consensus rating for BioScrip, Inc. (NASDAQ:BIOS) is Buy (Score: 3.00) with a consensus target price of $3.67 , a potential (37.84% upside)Recent Insider Trading for BioScrip, Inc. (NASDAQ:BIOS)
- On 11/11/2016 Jeffrey M Kreger, CFO, bought 10,000 with an average share price of $1.32 per share and the total transaction amounting to $13,200.00.
- On 11/10/2016 Daniel E Greenleaf, CEO, bought 16,000 with an average share price of $1.30 per share and the total transaction amounting to $20,800.00.
- On 11/10/2016 R Carter Pate, Director, bought 20,000 with an average share price of $1.30 per share and the total transaction amounting to $26,000.00.
- On 6/22/2016 Coliseum Capital Management, L, Director, bought 4,200,000 with an average share price of $2.00 per share and the total transaction amounting to $8,400,000.00.
- On 6/17/2016 David W Golding, Director, bought 12,500 with an average share price of $2.48 per share and the total transaction amounting to $31,000.00.
- On 8/24/2015 Coliseum Capital Management, L, Director, bought 789,503 with an average share price of $1.88 per share and the total transaction amounting to $1,484,265.64.
Recent Trading for BioScrip, Inc. (NASDAQ:BIOS) Shares of BioScrip, Inc. closed the previous trading session at 2.78 up +0.12 4.32% with 512,388 shares trading hands.